CYP2C9 genotype vs. metabolic phenotype for individual drug dosing—A correlation analysis using flurbiprofen as probe drug
S Vogl, RW Lutz, G Schönfelder, WK Lutz - PLoS One, 2015 - journals.plos.org
Currently, genotyping of patients for polymorphic enzymes responsible for metabolic
elimination is considered a possibility to adjust drug dose levels. For a patient to profit from …
elimination is considered a possibility to adjust drug dose levels. For a patient to profit from …
Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based …
ZE Barter, GT Tucker, K Rowland-Yeo - Clinical pharmacokinetics, 2013 - Springer
Abstract Background International Conference on Harmonization of Technical Requirements
for Registration of Pharmaceuticals for Human Use (ICH) guidelines emphasize the need for …
for Registration of Pharmaceuticals for Human Use (ICH) guidelines emphasize the need for …
Study on genotype and phenotype of novel CYP2D6 variants using pharmacokinetic and pharmacodynamic models with metoprolol as a substrate drug
J Qian, T Xu, P Pan, W Sun, G Hu, J Cai - The Pharmacogenomics …, 2024 - nature.com
To investigate the pharmacokinetic and pharmacodynamic profiles of volunteers carrying
CYP2D6 genotypes with unknow metabolic phenotypes, a total of 22 volunteers were …
CYP2D6 genotypes with unknow metabolic phenotypes, a total of 22 volunteers were …
Pharmacokinetic– pharmacodynamic analysis of the role of CYP2C19 genotypes in short‐term rabeprazole‐based triple therapy against Helicobacter pylori
JC Yang, YF Yang, YS Uang, CJ Lin… - British journal of …, 2009 - Wiley Online Library
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Asians have a higher percentage of
CYP2C19 poor metabolizers (PMs) and a high percentage of Helicobacter pylori infection …
CYP2C19 poor metabolizers (PMs) and a high percentage of Helicobacter pylori infection …
Predicting nonlinear pharmacokinetics of omeprazole enantiomers and racemic drug using physiologically based pharmacokinetic modeling and simulation …
Purpose The objective of this study is to develop a physiologically-based pharmacokinetic
(PBPK) model for each omeprazole enantiomer that accounts for nonlinear PK of the two …
(PBPK) model for each omeprazole enantiomer that accounts for nonlinear PK of the two …
Effect of high‐dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19
T Furuta, N Shirai, F Xiao, K Ohashi… - Clinical Pharmacology …, 2001 - Wiley Online Library
Backgrounds and Aim Lansoprazole is mainly metabolized by cytochrome P4502C19
(CYP2C19) in the liver. The effect of lansoprazole is assumed to be insufficient in subjects …
(CYP2C19) in the liver. The effect of lansoprazole is assumed to be insufficient in subjects …
Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 …
KR Yeo, JR Kenny, A Rostami-Hodjegan - European journal of clinical …, 2013 - Springer
Purpose To predict the impact of the CYP2C8* 3 genotype on rosiglitazone exposure in the
absence and presence of trimethoprim. Methods Prior in vitro and in vivo information for …
absence and presence of trimethoprim. Methods Prior in vitro and in vivo information for …
The hydroxylation of omeprazole correlates with S‐mephenytoin metabolism: A population study
JD Balian, N Sukhova, JW Harris… - Clinical …, 1995 - Wiley Online Library
We compared omeprazole and mephenytoin as probes for the CYP2C19 metabolic
polymorphism. Single oral doses of omeprazole (20 mg) or mephenytoin (100 mg) were …
polymorphism. Single oral doses of omeprazole (20 mg) or mephenytoin (100 mg) were …
Application of microdosed intravenous omeprazole to determine hepatic CYP2C19 activity
M Mahmoudi, KI Foerster, J Burhenne… - The Journal of …, 2021 - Wiley Online Library
Omeprazole is an established probe drug to assess cytochrome P450 (CYP) 2C19 activity
(phenotyping). Because it has nonlinear pharmacokinetics (PK) after oral administration …
(phenotyping). Because it has nonlinear pharmacokinetics (PK) after oral administration …
Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker
MJ Kim, JS Bertino Jr, A Gaedigk… - Clinical …, 2002 - Wiley Online Library
Background Literature addressing the effect of sex on cytochrome P450 (CYP) 2C19 activity
is conflicting. The exogenous female sex steroid hormones used in oral contraceptives are …
is conflicting. The exogenous female sex steroid hormones used in oral contraceptives are …